MRD Negative

Biomarker

Related News

Senti completes enrolment in SENTI-202 Phase I trial in relapsed or refractory AML

May 14, 2026

Senti Biosciences completed enrolment in its Phase I SENTI-202 trial in relapsed or refractory AML and said recent data showed deep, MRD-negative durable complete remissions. The company plans FDA talks in the first half of 2026 on a pivotal registration programme.

Phase 2 trial reports MRD-negative responses with cilta-cel in high-risk smoldering multiple myeloma

May 13, 2026

A phase 2 trial in high-risk smoldering multiple myeloma found all 20 patients treated with cilta-cel became MRD-negative within two months and remained so after 15.3 months. No disease progression, death, dose-limiting toxicities, or high-grade side effects were observed.